1. Musa AM, Khalil EAG, Raheem MA, Zijlstra EE, Ibrahim ME, Elhassan IM, Mukhtar MM & El-Hassan AM. (2002). The natural history of Sudanese post kala-azar dermal leishmaniasis: clinical, immunological, prognostic features. Annals of Tropical Medicine & Parasitology, 96:765-72.
2. Zijlstra EE, Musa AM, Khalil EAG, Elhassan IM & El-Hassan AM. (2003). Post Kala-azar dermal leishmaniasis. Lancet Infectious Diseases; 3:87-98.
3. Kamil A.A., Khalil E.A.G., Musa A.M., Modabber F., Mukhtar M.M., Ibrahim M.E., Zijlstra E.E., Sacks D., Smith P.G., Zicker F & Elhassan A.M. (2003). Alum-precipitated autoclaved L.major plus BCG, a candidate vaccine for visceral leishmaniasis: safety, skin delayed hypersensitivity response and dose finding in healthy volunteers. Transactions of the Royal Society of Tropical Medicine & Hygiene; 97(3):365–368.
4. Elmahdi, M., Elamin, E.M., Melville, S.E., Musa, A.M., Blackwell, J.M., Mukhtar, M.M., EL-Hassan, A.M. & Ibrahim, M.E. (2005). Sudanese mucosal leishmaniasis: isolation of a parasite within the Leishmania donovani complex that differs genotypically from L. donovani causing classical visceral leishmaniasis. Infection, Genetics and Evolution, 5: 29-33.
5. Khalil, E.A.G., Ayed, N.B., Musa, A.M., Muntaser, M.E., Mukhtar, M.M., Zijlstra, E.E., Elhassan, I.M., Smith, P.G., Kieny, M.P., Ghalib, H.W., Zicker, F., Modabber, F. & Elhassan, A.M. (2005). Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clinical & Experimental Immunology, 140: 349-353.
6. Musa, A.M., Khalil, E.A.G., Ismail, A., Elhassan, I.M., Fesharki, H., Khamesipour. A., Modabber, F., Zijlstra, E.E. & El-Hassan, A.M. (2005a). Safety, immunogenicity and possible efficacy of immunochemotherapy of persistent post kala-azar dermal leishmaniasis (PKDL). Sudanese Journal of Dermatology, 3 (2): 62-72.
7. Musa, A.M., Khalil, E.A.G., Hamad, S., Mahgoub, F., Elkadaru, A.M.Y.
8. Asrat, H., Musa, A.M., Royce, C. & Wasunna, M. (2005). Visceral leishmaniasis: New Health Tools Are Needed. PloSMedicine, 2(7): 590-594. & El Hassan, A.M. (2005b). Efficacy of Liposomal amphotericin B (AmBisome) in the treatment of persistent Post kala-azar dermal leishmaniasis (PKDL). Annals of Tropical Medicine and Parasitology, 99 (6): 563-569.
9. Elamin, W.M., Mukhtar M.M., Sahar, M. Bakhiet., Musa AM., Lamyaa, A. M. EL-Hassan., Nazik, E. Abdullah., Kadaru, A.M.Y. & EL-Hassan, A.M. (2005). An unusual case of mucosal leishmaniasis with cutaneous dissemination in Sudan and its epidemiological significance. Sudanese Journal of dermatology, 3(2): 88-91.
10. E.M. Elamin, S. Guerbouj, A.M. Musa, I. Guizani, E.A.G., Khalil, M.M., Mukhtar, A.M.Y. Elkadaro, H.S. Mohamed, M.E. Ibrahim, M.M. Abdel Hamid, M. El Azhari, A.M. El Hassan. (2005). Uncommon clinical presentations of cutaneous leishmaniasis in Sudan. Transactions of the Royal Society of Tropical Medicine & Hygiene, 99(11):803-8.
11. Ismail A; Khalil EAG; Musa AM; Elhassan IM; Ibrahim ME; Theander TG. & El-Hassan AM. (2006). The Pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: Does ultraviolet light (UVB) radiation play a role? Medical Hypothesis; 66:993-999.
12.Khalil EAG; Ahmed AE; Musa AM. & Muna H. Hussein. (2006). Antimony-induced cerebellar ataxia. Saudi Medical Journal; 27:90-92.
13.Khalil EAG, Musa AM, Modabber F and EL-Hassan AM. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study. Ann Trop Paediatr. 2006 Dec; 26(4):357-61.
14. Salih MA, Ibrahim ME, Blackwell JM, Miller EN, Khalil EA, EL-Hassan AM, Musa AM and Mohammed HS. IFNG and IFNGR1 gene polymorphisms and susceptibility to post-kala-azar dermal leishmaniasis in Sudan. Genes Immun. 2007 Jan; 8(1):75-8.
15.Miller EN, Fadl F, Mohammed HS, Elzein A, Jamieson SE, Cordell HJ, Peacock CS, Fakiola M, Raju M, Khalil EA, EL-Hassan AM, Musa AM, Ibrahim ME and Blackwell JM. Y chromosome Lineage- and Village-Specific Genes on Chromosomes 1p22 and 6q27 Control Visceral Leishmaniasis in Sudan. PLoS Genet. 2007 May 11; 3(5):e71.
16.NM Yousif, AM Musa, AM Elhassan, EAG Khalil & IM Elhassan. Anti- Glucose Regulated Protein 78 (GRP78) antibody responses in Alum/ALM + BCG vaccinee, visceral leishmaniasis, and Post Kala-azar Dermal leishmaniasis patients; Sudan JMS, Sep 2007, vol 2(3) , 175-178.
17. Musa AM, Khalil EAG, Mahgoub FA, Hamad S, Modabber F, Elkadaru AMY, Aboud MH, Noazin S and El- Hassan AM. Immunochemotherapy of persistent post kala-azar dermal leishmaniasis: a novel approach of treatment. Transactions of the Royal Society of Tropical Medicine & Hygiene; 2008, January, 102 (1), 53-63.
18. EAG Khalil, AM Musa, SHH Elgawi, I Gamar Eldawla, MO Elhassan, A Meshasha, KA Eljaleel, BM Younis, MEE Elfaki and AM El-Hassan. Revival of a focus of visceral leishmaniasis in central Sudan, Annals of Tropical Medicine & parasitology, 2008, January, 102 (1): 79-80.
19. Ismail WMA, Khalil EAG, Bygbjerg IC, Osman, FM, Musa AM and El-Hassan. Coverage & efficacy of BCG vaccination in displaced populations: a measure of effectiveness of expanded program of immunization, Khartoum Medical Journal; Vol (1), No. 1, Jan 2008, 30-33.
20. A H Elagib, A E Ahmed, A Hussein, A M Musa, E A G Khalil & A M El-Hassan. possible predisposing factors for thrombotic cerebrovascular accidents (CVAs) in Sudanese patients, SMJ, 2008, Feb, 29 (2), 304-6.
21.Ahmed A Nimir, Eltahir A G Khalil, Ahmed M Musa, Habab M Yassin and Ahmed M EL-Hassan. Evaluation of the particle gel diffusion technique for the detection of haemoglobin S in sudanese patients, Ann of Clin Biochem 2009; 46:114-116.
22.MME Mudawi, Sania, AI Shadad, IB Eltayeb, EAG Khalil, AM Musa and AK Muddathir. The Pharmacodynamic Interactions of Sodium Stibogluconate (SSG) and Paromomycin (PM) on Various Isolated Tissues Preparations, Research Journal of Pharmacology 2009; 3 (2): 26-30.
23. Musa AM, Sassan N, Khalil EAG and Modabber F. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration, Transactions of the Royal Society of Tropical Medicine & Hygiene, 2010; (104) 1-2.
24.Farouk S, Salih MA, Musa AM, Blackwell JM, Miller EN, Khalil EA, ElHassan AM, Ibrahim ME, Mohamed HS. Interleukin 10 Gene Polymorphisms and Development of Post Kala-Azar Dermal Leishmaniasis in a Selected Sudanese Population,
25. Hailu A, Musa AM, Balasegaram M, Yifru S, et al. (2010). Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin Sulphate in East Africa: a Multicentre, Open-Label, Randomized, Controlled Clinical Trial. PLoS Negl Trop Dis 4(10): e709.
Public Health Genomics 2009; Dec 29.
26. Musa AM, Brima Younis, Ahmed Fadlalla, Catherine Royce, Manica Balasegaram, Monique Wasunna, Asrat Hailu, Tansy Edwards, Raymond Omollo, Mahmoud Mudawi, Gilbert Kokwaro, Ahmed El-Hassan, Eltahir Khalil. (2010). Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: a Randomized, Open-Label, Dose-Finding Study. PLoS Negl Trop Dis 4(10): e855.
27.Hamad SH; Khalil EAG; Musa AM; Younis BM; Elfaki MEE; El-Hassan AM. Leishmania donovani: Genetic diversity of isolates from Sudan characterized by PCR-based RAPD. Experimental parasitology 2010; 125(4):389-93.
28.Elnojomi N; Musa AM; Younis BM; Elfaki M; El-Hassan AM & Khalil E. (2010). Surrogate markers of subtle renal injury in patients with visceral leishmaniasis. SJKDT,
29.SH Hamad; EAG Khalil; Musa AM, ME Ibrahim & AM EL-Hassan. (2010). In vitro induction of unresponsiveness to sodium stibogluconate in Leishmania donovani isolates from Sudan. KMJ, Vol 03, No. 02, pp.416-419. 21(5):872-5.
30.Hassan M.M., Elhassan A.M., Musa A.M., Osman O.F., El Raba’a F.M.A., Balkew M. &, Elhassan
31. Khalid KE, Mohammed EMA, Ahmed M Musa and Jingwu. (2010). Appropriate Induction of T regulatory cells and HBV tolerance: Implications for Immunotherapy of autoimmune diseases. Gezira Journal of Health Sciences, June (2010). I.M. (2010). Establishment and maintenance of a laboratory colony of the sandfly Phlebotomus orientalis (Diptera: Psychodidae), the vector of visceral leishmaniasis in Sudan. KMJ, Vol 03, No. 02, pp.420-424.
32.Tansy Edwards, Raymond Omollo, Eltahir AG Khalil, Sisay Yifru , Brima Musa, Ahmed Musa, Monique Wasunna, Peter G Smith, Catherine Royce, Sally Ellis, Manica Balasegaram and Asrat Hailu (2011). Single-dose Liposomal Amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized Controlled trial. Trials. Mar 6;12:66.
33.Sara H Hassabelgawi, Ahmed M Musa, Eltahir AG Khalil, Tamrat Abebe, Brima M Younis, Mona EE Eltahir, Ahmed M EL-Hassan, Asrat Hailu, Aldert Bart. (2011). Probable genetic hybrids between Leishmania species in Sudanese isolates. Journal of Microbiology and Antimicrobials Vol. 3(6), pp. 142-145
34.EAG Khalil, AM Musa, BM Younis, MEE Elfaki, EE Zijlstra, AM Elhassan. Blindness following visceral leishmaniasis (2011): a neglected post-Kala-azar complication, Trop Doct
35.Raymond Omollo, Neal Alexander, Tansy Edwards, Eltahir Khalil, Brima Musa, Abuzaid Abdalla, Monique Wasunna, Njenga Njoroge, Dedan Kinoti, George Kirigi,Thomas P.C. Dorlo, Sally Ellis, Manica Balasegaram and Ahmed Mudawi Musa (2011). Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials, Jun 30;12:166. . Jul;41(3):139-40.
36.Fakiola M, Miller EN, Fadl M, Mohamed HS, Jamieson SE, Francis RW, Cordell HJ, Peacock CS, Raju M, Khalil EA, Elhassan A, Musa AM, Silveira F, Shaw JJ, Sundar S, Jeronimo SM, Ibrahim ME, Blackwell JM (2011). Genetic and functional evidence implicating DLL1 as the gene that influences susceptibility to visceral leishmaniasis at chromosome 6q27. J Infect Dis,
37. Khalil EA, Elnour AA, Musa AM, Elagib AA, Hassab Elgawi SH, Ismail WM, Elzaki KE. (2011). Tuberculous Lymphadenitis: markers of disease and healing, 204(3):467-77.
West Afr J Med
38. Louran Z, Ahmed Mudawi Musa, Hanan. M. Tahir, Nazar A. Mohammed, Nazik M Nurelhuda, Muna Hassan Mustafa, Sara Hassan Mustafa, Abualbishr Alshreef, Dina Sami .Khalifa, Fatima Elhassan, Intisar Elfadil Saeed, Khalid Abdelmutalab ELmardib, Dalia Yahia M. El Khier, Yara Badreldin Elsheikh, Eltayeb A. Elsayed. (2012). Promoting access to high quality primary health care services in Sudan. http://www.who.int/evidence/en/.
39.Ahmed Musa, Eltahir Khalil, Asrat Hailu, Joseph Olobo, Manica Balasegaram, Raymond Omollo, Tansy Edwards, Brima Musa, Abuzaid Abdalla Abuzaid, Osama Ahmed, Ahmed Fadlalla, Ahmed EL-Hassan, Marius Mueller, Juma Rashid, Jane Mbui, Geoffrey Mucee, Simon Njoroge, Veronica Manduku, Alice Musibi, Geoffrey Mutuma, Fredrick Kirui, Hudson Lodenyo, Dedan Mutea, George Kirigi, Sisay Yifru, Getahun Mengistu, Zewdu Hurissa, Workagegnehu Hailu, Teklu Weldegebreal, Yalemtsehay Mekonnen, Hailemariam Tafes, Eyasu Makonnen, Serah Ndegwe, Patrick Sagaki, Sally Ellis, Robert Kimuti, Josephine Kesusu, Lawrence Muthami, Rhoda Owiti, John Kinuthia, Monique Wasunna (2012). Paromomycin sulphate monotherapy versus Sodium Stibogluconate /paromomycin combination for the treatment of primary visceral leishmaniasis: A multi-center, open, randomized controlled trial, PLoS Negl Trop Dis, Vol 6, 6. e1674.
40. Mahmoud Mudawi El tahir, Asma Mohammed Nur Gamil, Hala Abdelwahab DaffAllah, Ahmed Mudawi Musa. (2012). Prescribing Patterns of Statins in Sudanese Patients, SJRUM, 30 June 2012; (1), 10-12.
41.Elfaki ME, Khalil EA, De Groot AS, Musa AM, Gutiérrez Núñez A, Younis BM, Salih KA, El-Hassan AM. (2012). Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines, Hum Vaccin Immunother
42. Sara Noureldyme Mohamed, Eltahir Awad Gasim Khalil, Ahmed Mudawi Musa, Brima Younis Musa, Samia Ali Omer, Abdalla Hassan Sharief and Ahmed Mohamed EL-Hassan (2012). Anti-Leishmania donovani antibodies enhance promastigotes internalization into host macrophages. Journal of Microbiology and Antimicrobials (in press).
43. A M Musa, EAG Khalil, BM Younis, MEE Elfaki, MY Elamin, AOA Adam, HAA Mohamed, MMM Dafalla, AA Abuzaid, AM EL-Hassan.
Treatment-Based Strategy for the Management of Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in the Sudan (accepted)
44. Ahmed Mohamed EL Hassan, Eltahir Awad Gasim Khalil, Waleed Mohamed Elamin, Lamyaa Ahmed Mohamed EL Hassan, Mogtaba Elsaman Ahmed, Ahmed Mudawi Musa. Misdiagnosis of Post-Kala-azar Dermal Leishmaniasis (PKDL). (accepted)
45.Khalil EAG; Musa AM; Musa BY; Elfaki MEE; Elkadaru AMY; Zijlstra EE; El-Hassan AM. Post kala-azar dermal leishmaniasis: a perfect paradigm of Immune reconstitution syndrome in non-HIV/AIDS patients. (accepted)